CMUS-ABS and CCMUS: High-Risk States in Clonal Hematopoiesis
September 25, 2026
New Horizons in Leukemia Research:
Selected Papers in Focus
Background
Clonal hematopoiesis (CH) refers to the expansion of blood cells derived from a single mutated hematopoietic stem cell. It is associated with an increased risk of myeloid neoplasms (MNs) as well as cardiovascular and kidney disease.
Chronic myelomonocytic leukemia (CMML) is an overt myeloid neoplasm within this spectrum. Its core diagnostic criteria include peripheral blood monocytosis of at least 0.5 x 109 monocytes/L and monocytes accounting for at least 10% of leukocytes, blasts comprising less than 20% of cells in peripheral blood and bone marrow, as well as evidence of clonality (Arber et al., 2022).
The International Consensus Classification (ICC) additionally introduced the categories clonal monocytosis of undetermined significance (CMUS) and clonal cytopenia and monocytosis of undetermined significance (CCMUS). These entities describe clonal hematopoietic alterations with concurrent monocytosis that do not meet the diagnostic criteria for CMML. CCMUS is characterized by the additional presence of cytopenia.
Using clinical, genomic, and longitudinal data from 431,531 UK Biobank participants, Dunn et al. investigated the prevalence and clinical relevance of CMUS and CCMUS. The researchers distinguished CMUS with absolute monocytosis—at least 1.0 x 109 monocytes/L and at least 10% of leukocytes (CMUS-ABS)—from CMUS with relative monocytosis—at least 10% of leukocytes but an absolute monocyte count of at least 0.5 x 109 and less than 1.0 x 109 monocytes/L (CMUS-REL). CCMUS was assigned when cytopenia was also present.
Study Results in Detail
Prevalence and clinical relevance: CMUS and CCMUS were uncommon
among UK Biobank participants, with a combined prevalence of 0.4%. CMUS-ABS and
CCMUS had a mutation profile distinct from CMUS-REL: TET2 and
spliceosome-factor mutations, particularly SRSF2, were more frequent in
CMUS-ABS and CCMUS. In contrast, DNMT3A mutations predominated in
CMUS-REL, resembling the pattern seen in clonal hematopoiesis without
monocytosis.
Increased disease risk: CMUS-ABS and CCMUS were associated with a high risk of
myeloid neoplasms. The 10-year incidence was 9.1% for CMUS-ABS and 18.5% for
CCMUS, compared with 5.3% for clonal cytopenia of undetermined significance
(CCUS) without monocytosis. Myeloproliferative neoplasms (MPNs) were the most
frequent progression outcome in CMUS-ABS, whereas myelodysplastic neoplasms
(MDS) occurred most frequently in CCMUS. Progression to CMML was also observed.
CMUS-ABS and CCMUS were also associated with an increased risk of
cardiovascular disease as well as acute and chronic kidney disease.
More precise definitions: Men had higher relative and absolute monocyte counts; 70.6% of all CMUS/CCMUS cases were male. Dunn et al. therefore proposed sex-specific monocyte thresholds with higher thresholds for men: at least 0.6 x 109 monocytes/L and at least 11.5% of leukocytes. Cases with an isolated DNMT3A mutation had an indolent course and a low risk of progression. Excluding isolated DNMT3A mutations and introducing sex-specific monocyte thresholds improved risk stratification.
MoSAIC for identifying SRSF2-mutated
monocytosis: SRSF2 mutations were associated with elevated monocyte
counts and a high risk of myeloid neoplasms. Dunn et al. therefore
developed MoSAIC (Monocytosis with SRSF2 Automatically Inferred from
Counts), a machine-learning classifier that estimates the likelihood of an SRSF2
mutation in individuals with monocytosis using routine complete blood count
parameters. Independent prospective validation is required before clinical
implementation.

Conclusion
The
findings of Dunn et al. indicate that CMUS and CCMUS are clinically
relevant entities within the spectrum of clonal hematopoiesis and are
frequently associated with an increased risk of myeloid neoplasms. The authors
recommend refining the definitions through sex-specific monocyte thresholds and
exclusion of isolated DNMT3A mutations to enable more accurate risk
stratification.
References
Dunn WG et al. The prevalence and
clinical significance of clonal monocytosis. Blood 2026;147(25):3039–3050.
Arber DA et al. International Consensus
Classification of Myeloid Neoplasms and Acute Leukemias: integrating
morphologic, clinical, and genomic data. Blood 2022;140(11):1200–1228.
The author

»Do you have questions about CMUS and CCMUS, or would you like further information about the study? Please feel free to E-Mail me.«
Dr. rer. nat. Katharina Hörst